{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T07:16:48Z","timestamp":1788333408352,"version":"build-2803163510"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"29","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Haidian District Maternal and Child Health Hospital","award":["HFKT2026-08"],"award-info":[{"award-number":["HFKT2026-08"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,17]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Zuranolone and Brexanolone are Food and Drug Administration-approved novel agents for postpartum depression, yet real-world post-marketing safety data for the two drugs remain insufficient. This study aimed to systematically characterize their adverse event (AE) profiles via two authoritative pharmacovigilance databases, namely the Food and Drug Administration Adverse Event Reporting System (FAERS) and VigiAccess. FAERS data from Q1 2019 to Q3 2025 and VigiAccess data updated to November 2025 were extracted. Reporting odds ratio and proportional reporting ratio were adopted to screen and compare AE signals of the two drugs. A total of 631 primary suspect (PS) drug reports for Zuranolone and 102 for Brexanolone were extracted from FAERS, whereas 863 Zuranolone and 227 Brexanolone reports were obtained from VigiAccess. At the system organ class level, AEs associated with Zuranolone involved 22 SOCs in FAERS and 24 SOCs in VigiAccess, with the top three SOCs sorted by reported cases as follows: Nervous system disorders, Psychiatric disorders, and General disorders and administration site conditions (FAERS); Nervous system disorders, General disorders and administration site conditions, and Psychiatric disorders (VigiAccess). For Brexanolone, AEs retrieved from FAERS involved 16 SOCs, compared with 21 SOCs in VigiAccess; the top three SOCs by the number of reported cases were Injury, poisoning and procedural complications, General disorders and administration site conditions, and Psychiatric disorders. After signal screening in the FAERS database, a total of 78 positive signals (involving 9 SOCs) were identified for Zuranolone, whereas 10 positive signals (involving 4 SOCs) were detected for Brexanolone. Four SOCs were commonly implicated in the positive AE signals of both drugs, with the most commonly reported AEs including gait disturbance, exposure via breast milk, fatigue, and therapy cessation. Additionally, compared to Brexanolone, 5 SOCs were uniquely associated with Zuranolone, with the most commonly reported AEs such as vertigo, vision blurred, muscle twitching, somnolence, and loss of personal independence in daily activities. Zuranolone\u2019s AEs mainly involved nervous system disorders and Psychiatric disorders, while Brexanolone\u2019s primarily included Injury, poisoning and procedural complications, and Psychiatric disorders. This study would provide more safety reference data for the clinical use of two drugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000049845","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T21:03:52Z","timestamp":1784322232000},"page":"e49845","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Real-world adverse event profiles of Zuranolone and Brexanolone based on FAERS and VigiAccess databases: An observational study"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8839-9904","authenticated-orcid":false,"given":"Guanbo","family":"Xie","sequence":"first","affiliation":[{"name":"Department of Pharmacy, HaiDian District Maternal and Child Health Care Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huili","family":"Weng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chengde Maternity and Child Health care Hospital, Chengde, Hebei, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxian","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, HaiDian District Maternal and Child Health Care Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqun","family":"Chi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, HaiDian District Maternal and Child Health Care Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260902","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1186\/s12884-021-04016-9","article-title":"Prevalence and risk factors of postpartum depression in the Middle East: a systematic review and meta-analysis.","volume":"21","author":"Alshikh Ahmad","year":"2021","journal-title":"BMC Pregnancy Childbirth"},{"key":"R2-20260902","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1089\/jwh.2015.5346","article-title":"Suicidal ideation during the postpartum period.","volume":"25","author":"Bodnar-Deren","year":"2016","journal-title":"J Womens Health (Larchmt)"},{"key":"R3-20260902","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/jamapsychiatry.2017.4363","article-title":"Association of persistent and severe postnatal depression with child outcomes.","volume":"75","author":"Netsi","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"R4-20260902","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00737-015-0562-8","article-title":"Maternal depression from pregnancy to 4 years postpartum and emotional\/behavioural difficulties in children: results from a prospective pregnancy cohort study.","volume":"19","author":"Woolhouse","year":"2016","journal-title":"Arch Womens Ment Health"},{"key":"R5-20260902","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1017\/S0033291719000709","article-title":"Maternal mental health and infant emotional reactivity: a 20-year two-cohort study of preconception and perinatal exposures.","volume":"50","author":"Spry","year":"2020","journal-title":"Psychol Med"},{"key":"R6-20260902","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00737-023-01378-1","article-title":"Postmarketing safety profile of brexanolone: a pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS).","volume":"27","author":"Zhang","year":"2024","journal-title":"Arch Womens Ment Health"},{"key":"R7-20260902","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40263-019-00605-7","article-title":"Pharmacotherapy of postpartum depression: current approaches and novel drug development.","volume":"33","author":"Frieder","year":"2019","journal-title":"CNS Drugs"},{"key":"R8-20260902","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ogc.2018.04.007","article-title":"Pharmacologic treatment of perinatal depression.","volume":"45","author":"Kimmel","year":"2018","journal-title":"Obstet Gynecol Clin North Am"},{"key":"R9-20260902","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2147\/NDT.S466260","article-title":"Clinical utility of zuranolone for postpartum depression: a narrative review.","volume":"21","author":"Giannopoulos","year":"2025","journal-title":"Neuropsychiatr Dis Treat"},{"key":"R10-20260902","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1358\/dot.2018.55.9.3040864","article-title":"Brexanolone for the treatment of patients with postpartum depression.","volume":"55","author":"Morrison","year":"2019","journal-title":"Drugs Today (Barc)"},{"key":"R11-20260902","doi-asserted-by":"crossref","first-page":"e70513","DOI":"10.1002\/hsr2.70513","article-title":"FDA-approved zuranolone: first oral treatment for postpartum depression, ushering in a new era of hope; a narrative review.","volume":"8","author":"Haris","year":"2025","journal-title":"Health Sci Rep"},{"key":"R12-20260902","doi-asserted-by":"crossref","first-page":"699740","DOI":"10.3389\/fpsyt.2021.699740","article-title":"Brexanolone, a GABA(A) modulator, in the treatment of postpartum depression in adults: a comprehensive review.","volume":"12","author":"Edinoff","year":"2021","journal-title":"Front Psychiatry"},{"key":"R13-20260902","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0140-6736(17)31264-3","article-title":"Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial.","volume":"390","author":"Kanes","year":"2017","journal-title":"Lancet"},{"key":"R14-20260902","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1176\/appi.ajp.20220785","article-title":"Zuranolone for the treatment of postpartum depression.","volume":"180","author":"Deligiannidis","year":"2023","journal-title":"Am J Psychiatry"},{"key":"R15-20260902","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jamapsychiatry.2021.1559","article-title":"Effect of zuranolone vs placebo in postpartum depression: a randomized clinical trial.","volume":"78","author":"Deligiannidis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"R16-20260902","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1080\/13696998.2024.2334160","article-title":"Indirect comparisons of relative efficacy estimates of zuranolone and selective serotonin reuptake inhibitors for postpartum depression.","volume":"27","author":"Meltzer-Brody","year":"2024","journal-title":"J Med Econ"},{"key":"R17-20260902","doi-asserted-by":"crossref","first-page":"1425295","DOI":"10.3389\/fpsyt.2024.1425295","article-title":"Evaluating the safety and efficacy of zuranolone in the management of major depressive disorder and postpartum depression, with or without concurrent insomnia: a rigorous systematic review and meta-analysis.","volume":"15","author":"Raja","year":"2024","journal-title":"Front Psychiatry"},{"key":"R18-20260902","doi-asserted-by":"crossref","first-page":"1676051","DOI":"10.3389\/fnhum.2025.1676051","article-title":"Signal mining of botulinum toxin type a adverse events based on FAERS database and its implications for the treatment of cerebral palsy.","volume":"19","author":"Wang","year":"2025","journal-title":"Front Hum Neurosci"},{"key":"R19-20260902","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s00266-020-02027-z","article-title":"Adverse events associated with botox as reported in a food and drug administration database.","volume":"45","author":"Ahsanuddin","year":"2021","journal-title":"Aesthetic Plast Surg"},{"key":"R20-20260902","doi-asserted-by":"crossref","first-page":"e0333692","DOI":"10.1371\/journal.pone.0333692","article-title":"Real-world study of adverse events associated with sodium zirconium cyclosilicate based on FDA adverse event reporting system and VigiAccess database.","volume":"20","author":"Jia","year":"2025","journal-title":"PLoS One"},{"key":"R21-20260902","first-page":"6940183","article-title":"Acute renal failure in a patient with rivaroxaban-induced hypersensitivity syndrome: a case report with a review of the literature and of pharmacovigilance registries.","volume":"2020","author":"Marcelino","year":"2020","journal-title":"Case Rep Nephrol"},{"key":"R22-20260902","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajg.2022.10.012","article-title":"Pantoprazole associated dyspepsia hypocalcemia and hyponatremia: a disproportionality analysis in FDA adverse event reporting system (FAERS) database.","volume":"24","author":"Nair","year":"2023","journal-title":"Arab J Gastroenterol"},{"key":"R23-20260902","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1111\/bcp.15869","article-title":"Bioinformatics-guided disproportionality analysis of sevoflurane-induced nephrogenic diabetes insipidus using the FDA Adverse Event Reporting System database.","volume":"90","author":"Jacob","year":"2024","journal-title":"Br J Clin Pharmacol"},{"key":"R24-20260902","doi-asserted-by":"crossref","first-page":"1517773","DOI":"10.3389\/fpsyt.2025.1517773","article-title":"Post marketing safety assessment of the novel postpartum depression drug, Zuranolone: evidence from real-world pharmacovigilance analysis based on the FDA adverse event reporting system.","volume":"16","author":"Huang","year":"2025","journal-title":"Front Psychiatry"},{"key":"R25-20260902","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jad.2025.04.091","article-title":"A systematic analysis of safety profile of Brexanolone in real-world use based on FAERS database.","volume":"382","author":"Jiang","year":"2025","journal-title":"J Affect Disord"},{"key":"R26-20260902","doi-asserted-by":"crossref","first-page":"120313","DOI":"10.1016\/j.jad.2025.120313","article-title":"Real-world safety profile of zuranolone for postpartum depression: a FAERS analysis.","volume":"393","author":"Chen","year":"2026","journal-title":"J Affect Disord"},{"key":"R27-20260902","doi-asserted-by":"crossref","first-page":"1334694","DOI":"10.3389\/fphar.2023.1334694","article-title":"Efficacy and tolerability of zuranolone in patients with depression: a meta-analysis of randomized controlled trials.","volume":"14","author":"Qiu","year":"2023","journal-title":"Front Pharmacol"},{"key":"R28-20260902","doi-asserted-by":"crossref","first-page":"e2576","DOI":"10.1002\/hup.2576","article-title":"Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression.","volume":"32","author":"Kanes","year":"2017","journal-title":"Hum Psychopharmacol"},{"key":"R29-20260902","doi-asserted-by":"crossref","first-page":"116602","DOI":"10.1016\/j.ejmech.2024.116602","article-title":"Synthesis and evaluation of neuroactive steroids with novel pharmacophore at C-21 let identify a compound with advantageous PK profile and higher EC(50) and E(max) as PAM on GABAA receptor.","volume":"276","author":"Ma","year":"2024","journal-title":"Eur J Med Chem"},{"key":"R30-20260902","doi-asserted-by":"crossref","first-page":"8","DOI":"10.64719\/pb.4493","article-title":"The black book of psychotropic dosing and monitoring.","volume":"54","author":"DeBattista","year":"2024","journal-title":"Psychopharmacol Bull"},{"key":"R31-20260902","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/phar.2331","article-title":"Brexanolone for postpartum depression: clinical evidence and practical considerations.","volume":"39","author":"Leader","year":"2019","journal-title":"Pharmacotherapy"},{"key":"R32-20260902","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/ajhp\/zxz333","article-title":"Brexanolone for postpartum depression.","volume":"77","author":"Hutcherson","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"R33-20260902","doi-asserted-by":"crossref","first-page":"2045125320968658","DOI":"10.1177\/2045125320968658","article-title":"Intravenous brexanolone for postpartum depression: what it is, how well does it work, and will it be used?","volume":"10","author":"Faden","year":"2020","journal-title":"Ther Adv Psychopharmacol"},{"key":"R34-20260902","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/87551225241287383","article-title":"Zuranolone for the treatment of postpartum depression.","volume":"41","author":"St Onge","year":"2025","journal-title":"J Pharm Technol"},{"key":"R35-20260902","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.coph.2005.10.003","article-title":"GABA-based therapeutic approaches: GABAA receptor subtype functions.","volume":"6","author":"Rudolph","year":"2006","journal-title":"Curr Opin Pharmacol"},{"key":"R36-20260902","doi-asserted-by":"crossref","first-page":"108333","DOI":"10.1016\/j.neuropharm.2020.108333","article-title":"Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABA(A) receptor positive allosteric modulator.","volume":"181","author":"Althaus","year":"2020","journal-title":"Neuropharmacology"},{"key":"R37-20260902","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.pbb.2006.07.031","article-title":"Sulfated steroids as endogenous neuromodulators.","volume":"84","author":"Gibbs","year":"2006","journal-title":"Pharmacol Biochem Behav"},{"key":"R38-20260902","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1515\/revneuro-2018-0014","article-title":"GABAergic modulation of serotonergic neurons in the dorsal raphe nucleus.","volume":"30","author":"Hernandez-Vazquez","year":"2019","journal-title":"Rev Neurosci"},{"key":"R39-20260902","doi-asserted-by":"crossref","first-page":"13609","DOI":"10.1038\/s41598-017-13599-3","article-title":"Chronic antidepressant potentiates spontaneous activity of dorsal raphe serotonergic neurons by decreasing GABA(B) receptor-mediated inhibition of L-type calcium channels.","volume":"7","author":"Asaoka","year":"2017","journal-title":"Sci Rep"},{"key":"R40-20260902","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.anl.2023.11.009","article-title":"Vestibular compensation: neural mechanisms and clinical implications for the treatment of vertigo.","volume":"51","author":"Takeda","year":"2024","journal-title":"Auris Nasus Larynx"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049845","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T07:00:49Z","timestamp":1788332449000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":40,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000049845","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"2026-06-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}